Share this video  

ASCO GI 2021 | Latest news in gastric cancer from ASCO GI

Geoffrey Ku, MD, Memorial Sloan Kettering Cancer Center, New York, NY, explores key updates from the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, including the results of the FIGHT study in esophagogastric cancer, the findings of the use of ZW25, a bispecific antibody in HER2-positive tumors, as well as the approval of trastuzumab deruxtecan, an antibody-drug conjugate in HER2-positive gastric cancer by the FDA based on the results of the DESTINY-Gastric01 study. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).


Dr Ku reports Apexigen (consulting), AstraZeneca (research support), BMS (research support, consulting), Daiichi-Sankyo (research support), Merck (research support, consulting), Oncolys (research support), Pieris (research support, consulting), Zymeworks (research support).